Navigation Links
The therapeutic benefits of the human-animal bond
Date:11/30/2009

CHICAGONovember 30, 2009A pet owner knows the enormous joy and comfort that an animal can provide, especially in troubled times. Most pets are considered important members of the family and irreplaceable companions. A growing body of research now documents the value of the human-animal bond in child development, elderly care, mental illness, physical impairment, dementia, abuse and trauma recovery, and the rehabilitation of incarcerated youth and adults.

In two articles in a recent issue of Family Process, titled "Human-Animal Bonds I," (focused on the benefits of companion animals) and "Human-Animal Bonds II," (focused on their role in couple and family dynamics and family therapy), Dr. Froma Walsh reviews and distills the essence of this cutting-edge research. She examines how a bond with a pet can strengthen human resilience through times of crisis, persistent adversity, and disruptive transitions, such as relocation, divorce, widowhood, and adoption.

The well-being and healing that a pet can provide include a range of relational benefits, from stress reduction and playfulness, to loyal companionship, affection, comfort, security, and unconditional love. Pets also can be drawn into couple and family conflict. Women often do not leave abusive partners because of threats of abuse to a beloved pet.

Dr. Walsh says, "The powerful meaning and significance of companion animals is underestimated." Mental health professionals rarely consider these bonds in clinical assessment and intervention, with focus limited to human relationships. Profound attachments with petsand grief in their lossare often marginalized, seen as abnormal, or altogether ignored in theory, training, and practice, These two articles provide an essential overview to inform clinical scholars and practitioners of the potential benefits in facilitating positive growth for individuals, couples, and families when companion animals are included as members of the healin
'/>"/>

Contact: Bethany Carland-Adams
scholarlynews@wiley.com
781-388-8509
Wiley-Blackwell
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Four Senior Executives Join Orexigen(R) Therapeutics Management Team
2. Monogram Energy, Inc. Acquires Triad Therapeutics, Inc.
3. Greater certainty in monitoring 3 therapeutic medications is facilitated by new CRMs
4. Echo Therapeutics Announces $3 Million Financing
5. Cornerstone Therapeutics Appoints General Counsel
6. DIA Conference to Explore Components of Risk Management Plans As They Apply to Medicinal Products, Therapeutic Biologics and Vaccines
7. Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45%
8. Therapeutic Boarding School to Provide Services Nationally
9. Cell Therapeutics, Inc. (CTI) to Report Third Quarter Financial Results on November 5
10. Morphotek(R), Inc. Announces a Licensing Deal With Centocor Ortho Biotech Inc. for Exclusive Development and Commercialization Rights for a Therapeutic Monoclonal Antibody
11. Sorrento Therapeutics Announces the Appointment of Martina Molsbergen as Vice President, Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... After a particularly harsh winter, many roads are ... to costly damage, so Amica Insurance has tips ... following suggestions from AAA: , , Inspect ... to the manufacturer’s recommended levels. , ... uneven tire wear can be signs of bad shocks or ...
(Date:4/1/2015)... Taking an important step forward in the continuing ... for Nursing Education Accreditation (NLN CNEA) , the League’s ... Board of Commissioners. Working with executive director Judith A. ... provide leadership and direction to accreditation services and will ... programs that seek accreditation from the CNEA. , “The ...
(Date:4/1/2015)... BioPlus Specialty Pharmacy (BioPlus), ... released a new app to keep health care providers ... hepatitis C virus (HCV) infection. This ‘HCV Treatment Path’ ... the American Association for the Study of Liver Diseases ... direct-acting oral medications to treat HCV have been approved ...
(Date:4/1/2015)... Seattle, WA (PRWEB) April 01, 2015 ... management and patient scheduling platform, today announced that CEO ... 2015 Annual HIMSS Conference & Exhibition in ... Outpatient Revenue Growth with Better Provider Care Coordination Strategies ... April 16 at 12 p.m. CDT. More than 38,000 ...
(Date:4/1/2015)... Parents of teenaged and adolescent children might want ... post discusses Teen Violence Related to Substance Abuse. As ... Awareness Month, the substance abuse treatment center has issued ... identify if there may be problems with their kids ... alcohol. , “People learn how to establish healthy relationships ...
Breaking Medicine News(10 mins):Health News:Prepare for potholes with 7 tips from Amica Insurance 2Health News:NLN Commission for Nursing Education Accreditation (NLN CNEA) Announces Inaugural Commissioners 2Health News:NLN Commission for Nursing Education Accreditation (NLN CNEA) Announces Inaugural Commissioners 3Health News:BioPlus Specialty Pharmacy Releases ‘HCV Treatment Path’ App for Hepatitis C Providers 2Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 2Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 3Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 4Health News:Best Drug Rehabilitation Issues Toolkit for Teen Violence Related to Substance Abuse 2
... , American Academy ... , ROSEMONT, Ill., July 23 The American Academy ... a nonprofit organization dedicated to collecting and reporting on hip and knee ... best practice. , , The goal ...
... July 23 /PRNewswire-FirstCall/ - Hard to Treat Diseases, ... in its Slavica BioChem division have advised of ... use of Ribavirin in the treatment of Multiple ... conducting experiments using Dark Agouti rats. Experimental ...
... , ROANOKE, Va., July 23 Job ... The Virginia Psychological Association (VPA) and Virginia Academy of Clinical ... this cost by awarding the 2009 VPA/VACP Psychologically Healthy Workplace ... submit nominations. , , ...
... , , SPOKANE, ... in partnership with eHealth Initiative will hold the Northwest ... featuring national and regional speakers on September 10 and ... and rural healthcare professionals to learn about the latest ...
... Medical Technologies, Inc. (Nasdaq: PMTI ), a leading ... hold its quarterly conference call of its 2009 second quarter ... Eastern Time. If you would like to participate, please call ... The telephone replay will be available one hour after the ...
... read my mind, love, what a tale my thoughts could ... people,s minds? Some researchers, and some new businesses, are banking ... imaging (fMRI) to reveal hidden thoughts, such as lies, truths ... neuroscientists at UCLA and Rutgers University provides evidence that fMRI ...
Cached Medicine News:Health News:American Joint Replacement Registry Announced 2Health News:Hard to Treat Diseases, Inc. (HTDS) Reports on Ribavirin Research as Potential Treatment for MS 2Health News:Hard to Treat Diseases, Inc. (HTDS) Reports on Ribavirin Research as Potential Treatment for MS 3Health News:INHS Brings Health Information Technology Conference to Spokane 2Health News:Palomar Medical Technologies To Host Second Quarter 2009 Financial Results Conference Call and Webcast on July 30, 2009 2Health News:Can brain scans read your mind? 2Health News:Can brain scans read your mind? 3
(Date:4/1/2015)... 1, 2015 Trinity Biotech plc (Nasdaq: ... of diagnostic products for the point-of-care and clinical ... Limited, its wholly-owned subsidiary (the "Issuer"), intends to ... million aggregate principal amount of Exchangeable Senior Notes ... institutional buyers pursuant to Rule 144A under the ...
(Date:4/1/2015)... 1, 2015  Pittman Motors has significantly expanded ... PLG42K, PLG42S, PLG52, and PLG63 planetary gearboxes. These ... brushless DC motors and complement Pittman,s existing spur ... 35 standard motor-gearbox family combinations to the Pittman ... high torque loads with excellent efficiency and are ...
(Date:4/1/2015)... MOUNTAIN VIEW, Calif. , April 1, ... ) announces that it has signed a definitive ... device company that develops, manufactures and sells minimally ... drainage of targeted areas within the gastrointestinal tract. ... The Xlumena portfolio includes the ...
Breaking Medicine Technology:Trinity Biotech plc Announces Proposed Offering of $100 Million of Exchangeable Senior Notes due 2045 2Trinity Biotech plc Announces Proposed Offering of $100 Million of Exchangeable Senior Notes due 2045 3Trinity Biotech plc Announces Proposed Offering of $100 Million of Exchangeable Senior Notes due 2045 4Pittman Motors Expands PLG Planetary Gearbox Offering 2Boston Scientific Agrees to Acquire Xlumena 2Boston Scientific Agrees to Acquire Xlumena 3Boston Scientific Agrees to Acquire Xlumena 4Boston Scientific Agrees to Acquire Xlumena 5
... Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: ... specializing in the development, manufacturing, and marketing of ... that Shanghai Celgen Bio-Pharmaceutical Co., Ltd. ("Shanghai Celgen") ... interest, has received new drug registration approval for ...
... Cempra Pharmaceuticals, a developer of differentiated antibiotics, ... (IV) solithromycin demonstrates excellent tolerability and ... up to 800 mg.  Oral administration of solithromycin ... 1 studies.  The presentation will be at the ...
Cached Medicine Technology:Simcere Announces Recent Progress of Qiangke's Registration 2Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 2Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 3Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 4Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 5Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 6Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 7
Inquire...
Inquire...
One Pair of Knife Raising Blocks to move blade up 1 inch for adpatation of a freezing stage....
Supercassette quick release holder for the 8000 Series sliding microtome to allow for the use of wax supercassettes, 75x52x19 mm....
Medicine Products: